Symbols

UBX(Delisted)

Unity Biotechnology·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About UBX

Unity Biotechnology, Inc.

A biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging

Industry

Established Date

Listing Date

05/03/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.unitybiotechnology.com

Security Type

Common stock

Office address

285 East Grand Ave. , South San Francisco, CA 94080

Business

Introduction

Unity Biotechnology, Inc., was incorporated in Delaware in March 2009. The company is a biotechnology company engaged in the research and development of therapies to slow down, stop or reverse the disease of aging. The company's initial focus is to develop anti-aging drugs that selectively eliminate senescent cells to treat aging diseases such as ophthalmological diseases.

Company Financials

EPS

UBX has released its 2025 Q1 earnings. EPS was reported at -0.43, versus the expected -0.4, missing expectations. The chart below visualizes how UBX has performed over recent quarters, highlighting trends in earnings surprises.